Johnson & Johnson Releases OMNY-AF Study Data
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Should l Buy JNJ?
Source: Businesswire
- Study Success Rate: The OMNY-AF study reported a 100% acute procedural success rate among 30 patients with no procedure-related adverse events, indicating the platform's potential in treating paroxysmal atrial fibrillation and possibly enhancing future clinical applications.
- Fluoroscopy-Free Procedures: Notably, 56.7% of cases were performed without fluoroscopy, and 90% of patients achieved primary effectiveness at 12 months, which not only reduces patient radiation exposure risks but may also enhance patient treatment experience and satisfaction.
- Multi-Center Trial: Conducted across over 40 sites in the U.S. and Australia, the OMNY-AF study highlights Johnson & Johnson's extensive footprint in cardiac electrophysiology, with large-scale data supporting the efficacy and safety of its technologies in the future.
- VARIPULSE Platform Data: The VARIPULSE platform demonstrated a low neurovascular event rate of 0.22% in 6,811 patients, further validating its safety profile and potentially increasing physician confidence in the technology, thereby promoting its clinical adoption.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy JNJ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on JNJ
Wall Street analysts forecast JNJ stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for JNJ is 218.50 USD with a low forecast of 190.00 USD and a high forecast of 240.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
20 Analyst Rating
13 Buy
7 Hold
0 Sell
Moderate Buy
Current: 237.790
Low
190.00
Averages
218.50
High
240.00
Current: 237.790
Low
190.00
Averages
218.50
High
240.00
About JNJ
Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Investors Nervous About Robinhood's Bitcoin Correlation
- Labor Data Impact: The upcoming nonfarm payroll report on Wednesday is expected to show an addition of 80,000 jobs, and if the data comes in weak, it could lead the Fed to continue cutting rates, which would positively impact the stock market, reflecting concerns about economic slowdown.
- CVS Health Earnings Outlook: CVS Health is set to report quarterly results on Tuesday, and despite being affected by the Trump administration's proposed reimbursement rates for Medicare Advantage, Cramer believes CEO David Joyner's management is impressive and the stock is worth owning.
- DuPont Performance Highlights: DuPont's earnings report on the same day is expected to showcase CEO Lori Koch's success in improving the company's performance, with the stock soaring 58% over the past six months, reflecting the effectiveness of its electronics business spin-off strategy.
- Robinhood Trading Risks: Robinhood will report earnings on Tuesday, and due to its close correlation with cryptocurrency markets, investors are concerned, as the stock has dropped nearly 27% year-to-date, significantly underperforming the S&P 500's 1.3% gain.
See More
Johnson & Johnson Releases OMNY-AF Study Data
- Study Success Rate: The OMNY-AF study reported a 100% acute procedural success rate among 30 patients with no procedure-related adverse events, indicating the platform's potential in treating paroxysmal atrial fibrillation and possibly enhancing future clinical applications.
- Fluoroscopy-Free Procedures: Notably, 56.7% of cases were performed without fluoroscopy, and 90% of patients achieved primary effectiveness at 12 months, which not only reduces patient radiation exposure risks but may also enhance patient treatment experience and satisfaction.
- Multi-Center Trial: Conducted across over 40 sites in the U.S. and Australia, the OMNY-AF study highlights Johnson & Johnson's extensive footprint in cardiac electrophysiology, with large-scale data supporting the efficacy and safety of its technologies in the future.
- VARIPULSE Platform Data: The VARIPULSE platform demonstrated a low neurovascular event rate of 0.22% in 6,811 patients, further validating its safety profile and potentially increasing physician confidence in the technology, thereby promoting its clinical adoption.
See More
OMNY-AF Study Reports 90% Freedom from AFib at 12 Months
- Significant Study Results: The OMNY-AF trial demonstrated that 90% of the 30 patients achieved freedom from atrial fibrillation (AFib) at 12 months, with a 100% acute procedural success rate, underscoring the effectiveness and safety of the OMNYPULSE platform.
- No Adverse Events: Conducted across over 40 centers, the study reported no procedure-related adverse events throughout the trial, further reinforcing confidence in the OMNYPULSE platform's application in cardiac electrophysiology.
- Outstanding VARIPULSE Performance: Following workflow enhancements, the VARIPULSE platform exhibited a low neurovascular event rate of just 0.22% in 6,811 patients, demonstrating its safety and efficacy in clinical applications and supporting broader adoption of this technology.
- Commitment to Continuous Innovation: Johnson & Johnson is dedicated to evidence-driven innovation that enhances patient care, leveraging the leading CARTO 3 system technology to advance the field of cardiac electrophysiology and ensure safer, more effective treatment options for patients.
See More
Soft Jobs Report Could Impact Stock Market Next Week
- Job Data Focus: Cramer emphasized the importance of the nonfarm payroll report due next Wednesday, suggesting that a soft reading could lead the Fed to continue cutting rates, which would positively impact the stock market and reflect market expectations of economic slowdown.
- Earnings Reports Ahead: Several companies, including CVS Health, Robinhood, and DuPont, are set to report earnings next week; Cramer believes CVS is the only drug retailer worth owning amid Medicare reform, showcasing its competitive edge in the market.
- DuPont's Strong Performance: Cramer anticipates that DuPont's earnings report will highlight CEO Lori Koch's effective management, particularly after the spinoff of its electronics business, with the stock soaring 58% over the past six months, indicating the success of the company's restructuring.
- McDonald's and Cisco Outlook: Cramer noted that McDonald's maintains a competitive advantage despite beef inflation, while Cisco's stock has risen 10% year-to-date, with both earnings reports expected to provide critical market signals for investors.
See More
The Dow Exceeded 50,000: The Role of Caterpillar and Other Stocks in This Milestone.
Stock Market Surge: The stock market experienced a significant rebound, with the Dow Jones Industrial Average increasing by over 1,000 points.
Historic Milestone: This surge allowed the Dow to surpass the 50,000 mark for the first time in history.
See More
The Dow Approaches 50,000, and It's Not Driven by Technology.
Market Performance: The stock market experienced a significant rebound, with the Dow Jones Industrial Average increasing by over 1,000 points.
Historic Milestone: This surge pushed the Dow above 50,000 for the first time in history.
See More
Investors Nervous About Robinhood's Bitcoin Correlation
- Labor Data Impact: The upcoming nonfarm payroll report on Wednesday is expected to show an addition of 80,000 jobs, and if the data comes in weak, it could lead the Fed to continue cutting rates, which would positively impact the stock market, reflecting concerns about economic slowdown.
- CVS Health Earnings Outlook: CVS Health is set to report quarterly results on Tuesday, and despite being affected by the Trump administration's proposed reimbursement rates for Medicare Advantage, Cramer believes CEO David Joyner's management is impressive and the stock is worth owning.
- DuPont Performance Highlights: DuPont's earnings report on the same day is expected to showcase CEO Lori Koch's success in improving the company's performance, with the stock soaring 58% over the past six months, reflecting the effectiveness of its electronics business spin-off strategy.
- Robinhood Trading Risks: Robinhood will report earnings on Tuesday, and due to its close correlation with cryptocurrency markets, investors are concerned, as the stock has dropped nearly 27% year-to-date, significantly underperforming the S&P 500's 1.3% gain.
See More
Johnson & Johnson Releases OMNY-AF Study Data
- Study Success Rate: The OMNY-AF study reported a 100% acute procedural success rate among 30 patients with no procedure-related adverse events, indicating the platform's potential in treating paroxysmal atrial fibrillation and possibly enhancing future clinical applications.
- Fluoroscopy-Free Procedures: Notably, 56.7% of cases were performed without fluoroscopy, and 90% of patients achieved primary effectiveness at 12 months, which not only reduces patient radiation exposure risks but may also enhance patient treatment experience and satisfaction.
- Multi-Center Trial: Conducted across over 40 sites in the U.S. and Australia, the OMNY-AF study highlights Johnson & Johnson's extensive footprint in cardiac electrophysiology, with large-scale data supporting the efficacy and safety of its technologies in the future.
- VARIPULSE Platform Data: The VARIPULSE platform demonstrated a low neurovascular event rate of 0.22% in 6,811 patients, further validating its safety profile and potentially increasing physician confidence in the technology, thereby promoting its clinical adoption.
See More
OMNY-AF Study Reports 90% Freedom from AFib at 12 Months
- Significant Study Results: The OMNY-AF trial demonstrated that 90% of the 30 patients achieved freedom from atrial fibrillation (AFib) at 12 months, with a 100% acute procedural success rate, underscoring the effectiveness and safety of the OMNYPULSE platform.
- No Adverse Events: Conducted across over 40 centers, the study reported no procedure-related adverse events throughout the trial, further reinforcing confidence in the OMNYPULSE platform's application in cardiac electrophysiology.
- Outstanding VARIPULSE Performance: Following workflow enhancements, the VARIPULSE platform exhibited a low neurovascular event rate of just 0.22% in 6,811 patients, demonstrating its safety and efficacy in clinical applications and supporting broader adoption of this technology.
- Commitment to Continuous Innovation: Johnson & Johnson is dedicated to evidence-driven innovation that enhances patient care, leveraging the leading CARTO 3 system technology to advance the field of cardiac electrophysiology and ensure safer, more effective treatment options for patients.
See More
Soft Jobs Report Could Impact Stock Market Next Week
- Job Data Focus: Cramer emphasized the importance of the nonfarm payroll report due next Wednesday, suggesting that a soft reading could lead the Fed to continue cutting rates, which would positively impact the stock market and reflect market expectations of economic slowdown.
- Earnings Reports Ahead: Several companies, including CVS Health, Robinhood, and DuPont, are set to report earnings next week; Cramer believes CVS is the only drug retailer worth owning amid Medicare reform, showcasing its competitive edge in the market.
- DuPont's Strong Performance: Cramer anticipates that DuPont's earnings report will highlight CEO Lori Koch's effective management, particularly after the spinoff of its electronics business, with the stock soaring 58% over the past six months, indicating the success of the company's restructuring.
- McDonald's and Cisco Outlook: Cramer noted that McDonald's maintains a competitive advantage despite beef inflation, while Cisco's stock has risen 10% year-to-date, with both earnings reports expected to provide critical market signals for investors.
See More
The Dow Exceeded 50,000: The Role of Caterpillar and Other Stocks in This Milestone.
Stock Market Surge: The stock market experienced a significant rebound, with the Dow Jones Industrial Average increasing by over 1,000 points.
Historic Milestone: This surge allowed the Dow to surpass the 50,000 mark for the first time in history.
See More
The Dow Approaches 50,000, and It's Not Driven by Technology.
Market Performance: The stock market experienced a significant rebound, with the Dow Jones Industrial Average increasing by over 1,000 points.
Historic Milestone: This surge pushed the Dow above 50,000 for the first time in history.
See More
